Mark H H Kramer Selected Research

insulin glulisine

1/2019	Renal tubular effects of prolonged therapy with the GLP-1 receptor agonist lixisenatide in patients with type 2 diabetes mellitus.
1/2018	Effect of immediate and prolonged GLP-1 receptor agonist administration on uric acid and kidney clearance: Post-hoc analyses of four clinical trials.
1/2018	Lixisenatide Versus Insulin Glulisine on Fasting and Postbreakfast Systemic Hemodynamics in Type 2 Diabetes Mellitus Patients.
12/2017	Postprandial renal haemodynamic effect of lixisenatide vs once-daily insulin-glulisine in patients with type 2 diabetes on insulin-glargine: An 8-week, randomised, open-label trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Mark H H Kramer Research Topics

Disease

36	Type 2 Diabetes Mellitus (MODY) 01/2022 - 01/2010
16	Overweight 01/2022 - 12/2014
7	Body Weight (Weight, Body) 01/2022 - 04/2016
3	Pneumonia (Pneumonitis) 08/2022 - 12/2006
3	Weight Loss (Weight Reduction) 01/2022 - 01/2016
3	Obesity 01/2022 - 01/2022
3	Insulin Resistance 01/2020 - 01/2010
3	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 10/2017 - 08/2015
2	Neoplasms (Cancer) 08/2022 - 08/2003
2	Fever (Fevers) 08/2022 - 04/2007
2	Infections 08/2022 - 04/2017
2	Hypotension (Low Blood Pressure) 01/2021 - 10/2020
2	Hyperglycemia 01/2020 - 04/2017
2	Delirium 01/2018 - 08/2014
2	Hypoglycemia (Reactive Hypoglycemia) 10/2017 - 08/2015
2	Diabetic Nephropathies (Diabetic Nephropathy) 10/2017 - 05/2015
2	Cardiovascular Diseases (Cardiovascular Disease) 04/2017 - 02/2009
2	Head and Neck Neoplasms (Head and Neck Cancer) 01/2016 - 10/2013
2	Protein C Deficiency 09/2007 - 07/2003
2	Venous Thromboembolism 06/2007 - 02/2007
2	Pulmonary Embolism 02/2007 - 01/2006
2	Thrombosis (Thrombus) 07/2003 - 12/2002
2	Venous Thrombosis (Deep-Vein Thrombosis) 07/2003 - 12/2002
1	Fever of Unknown Origin 08/2022
1	Neutropenia 08/2022
1	Febrile Neutropenia 08/2022
1	Respiratory Insufficiency (Respiratory Failure) 08/2022
1	Septic Shock (Toxic Shock Syndrome) 08/2022
1	COVID-19 01/2022
1	Lymphadenopathy 01/2021
1	Sarcoidosis (Schaumann Disease) 01/2021
1	Granuloma 01/2021
1	Ketosis 12/2020

Drug/Important Bio-Agent (IBA)

17	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 01/2010
10	Exenatide (Byetta)FDA Link 01/2022 - 06/2015
10	Metformin (Glucophage)FDA LinkGeneric 01/2022 - 12/2016
8	Glucagon-Like Peptide-1 Receptor AgonistsIBA 01/2022 - 09/2013
8	Liraglutide FDA Link 01/2021 - 11/2016
8	Glucagon-Like Peptide-1 ReceptorIBA 03/2019 - 06/2015
7	Sitagliptin Phosphate (Januvia)FDA Link 01/2021 - 11/2016
7	Glucagon-Like Peptide 1 (GLP 1)IBA 01/2019 - 01/2010
6	dapagliflozinIBA 01/2022 - 01/2020
6	Insulin (Novolin)FDA Link 01/2020 - 01/2010
5	Pharmaceutical PreparationsIBA 08/2022 - 08/2014
5	AnticoagulantsIBA 06/2007 - 07/2003
4	Dipeptidyl-Peptidase IV InhibitorsIBA 11/2020 - 10/2016
4	Insulin Glargine (Lantus)FDA Link 01/2019 - 01/2017
4	insulin glulisine FDA Link 01/2019 - 12/2017
4	lixisenatideIBA 01/2019 - 12/2017
3	Anti-Bacterial Agents (Antibiotics)IBA 08/2022 - 12/2006
3	SodiumIBA 01/2022 - 11/2019
3	LinagliptinIBA 01/2022 - 10/2020
3	glimepiride (Amarel)FDA LinkGeneric 01/2022 - 10/2020
3	Sodium-Glucose Transport ProteinsIBA 12/2020 - 04/2017
3	Gliclazide (Diamicron)IBA 12/2020 - 01/2020
3	Dipeptidyl Peptidase 4 (Dipeptidyl Peptidase IV)IBA 11/2020 - 04/2016
3	IncretinsIBA 10/2017 - 11/2015
3	Dipeptidyl-Peptidases and Tripeptidyl-PeptidasesIBA 12/2016 - 11/2015
3	Glucagon-Like Peptides (Enteroglucagon)IBA 12/2016 - 11/2015
2	Sodium-Glucose Transporter 2 InhibitorsIBA 12/2020 - 01/2020
2	Inulin FDA Link 01/2020 - 01/2020
2	Glucagon-Like Peptide ReceptorsIBA 11/2019 - 12/2017
2	Hypoglycemic Agents (Hypoglycemics)IBA 11/2019 - 08/2015
2	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 01/2019 - 10/2016
2	Haloperidol (Haldol)FDA LinkGeneric 01/2018 - 08/2014
2	CreatinineIBA 12/2017 - 11/2016
2	AlbuminsIBA 12/2017 - 11/2016
2	EnzymesIBA 03/2017 - 04/2016
2	PlacebosIBA 12/2016 - 11/2016
2	GoldIBA 11/2016 - 08/2015
2	Prothrombin (Factor II)IBA 09/2007 - 07/2003
2	fibrin fragment D (D-dimer)IBA 01/2006 - 12/2002
1	Carbapenems (Carbapenem Antibiotics)IBA 08/2022
1	Meropenem (Merrem)FDA LinkGeneric 08/2022
1	Imipenem Drug Combination Cilastatin (Primaxin)FDA Link 08/2022
1	Antihypertensive Agents (Antihypertensives)IBA 01/2021
1	Polyurethanes (Polyurethane)IBA 01/2021
1	Polyethylene Terephthalates (Polyethylene Terephthalate)IBA 01/2021
1	SiliconesIBA 01/2021
1	Chenodeoxycholic Acid (Chenix)FDA Link 01/2021
1	Cholic AcidIBA 01/2021
1	Bile Acids and Salts (Bile Acids)IBA 01/2021
1	Ursodeoxycholic Acid (Urso)FDA LinkGeneric 01/2021
1	Deoxycholic Acid (Sodium Deoxycholate)IBA 01/2021
1	ElectrolytesIBA 12/2020
1	boldenone undecylenate (Equipoise)IBA 12/2020
1	MagnesiumIBA 12/2020
1	AcidsIBA 12/2020
1	Phosphates (Orthophosphate)IBA 12/2020
1	p-Aminohippuric Acid (p-Aminohippurate)FDA Link 01/2020

Therapy/Procedure

11	Therapeutics 01/2022 - 02/2007
3	Drug Therapy (Chemotherapy) 08/2022 - 08/2003
3	Glycemic Control 12/2020 - 08/2015
3	Length of Stay 01/2019 - 12/2006
2	Radiotherapy 01/2016 - 10/2013
2	Activities of Daily Living (ADL) 08/2014 - 12/2013
1	Stem Cell Transplantation 08/2022
1	Patient Transfer (Patient Dumping) 01/2022
1	Lasers (Laser) 01/2021
1	Breast Implants (Breast Implant) 01/2021